Clinigen Group Acquires U.S. Rights to Proleukin from Novartis

London-based Clinigen Group pc now has full rights to Proleukin (aldesleukin, human recombinant interleukin-2). This morning, the U.K.-based pharmaceutical and services company struck a deal with Novartis to acquire the U.S. rights to the metastatic renal cell carcinoma treatment.